Now, keep up to date
with daily feeds of newly posted stories
about America's Seniors...click on the box
to the left
Reaching
toward the Fountain of Youth
Newswise, December 10, 2010 — Sometimes the
value of research lies as much in exposing
false remedies as in discovering true
breakthroughs. Scientists at the country's
first school of gerontology and in
laboratories around the University of
Southern California do both, mindful of
their responsibility to a society focused on
healthful aging.
TO UNDERSTAND
THE PROMISE and pitfalls of anti-aging
therapies, start with the research and
lifestyles of anti-aging scholars.
Valter Longo
knows how to give yeast cells 10 lives, but
neither he nor any other biologist knows for
sure how to add even one year to the human
lifespan. So Longo plays the Longevity
Casino with a conservative strategy:
exercise moderately, follow the Okinawa diet
(whole grains, vegetables and fish) and
leave the table a little hungry.
Christian Pike
believes in a link between low hormone
levels and Alzheimer’s disease, and he has
seen how middle-aged mice perk up when given
testosterone.
Yet he is
leery enough of potential side effects that
he advises his own parents not to take
hormone supplements, and jokes that so far
he has resisted the temptation to dip into
his laboratory’s testosterone stock.
Caleb Finch, a
world authority on inflammation and aging,
takes statins to control his cholesterol
level, and also because the drugs appear to
tame damaging inflammatory substances. He
swims regularly but does not like to push
his body too hard.
These experts’
ambitious research programs embody the
promise of anti-aging medicine. Their
lifestyles reflect their modest personal
approaches to longevity. Nowhere is the rift
between theory and practice wider than in
the pursuit of longer, healthier lives.
The 1990s were
supposed to break open the promise of gene
therapy. Tom Johnson of the University of
Colorado startled the research world in 1990
by reporting that the mutation of a single
gene could more than double the maximum
lifespan of earthworms. Confirmed and
extended by Cynthia Kenyon of UC San
Francisco in 1993, the experiments showed
that the mutated worms not only lived
longer, but also looked younger and fitter.
Scientists
then achieved lifespan extension of 30 to 50
percent in genetically engineered mice. By
2008, at the USC Davis School of Gerontology
- the first such school in the country -
Longo’s laboratory had achieved a record
tenfold lifespan extension in genetically
engineered baker’s yeast.
Genetically
engineered humans are a different brew, for
both ethical and technical reasons. In a
2010 review of lifespan extension in the
journal Science, Longo noted the lack of
mutation studies even on monkeys and other
primates. If and when such studies are done,
results will not arrive for decades due to
the long lifespan of the animals. Ethical
questions about gene therapy and genetic
engineering in humans guarantee additional,
possibly indefinite, delays.
The efficacy
of longevity therapies marketed today will
not be proven for at least a generation.
Nature abhors a vacuum, and scammers are
quick to spot an opportunity. The anti-aging
industry is an obvious magnet for
charlatans.
Yet in theory,
the genetic study of longevity holds vast
potential. If scientists can identify
genetic mutations that prolong lifespan -
and a few strong candidates have emerged
from studies of centenarians around the
world - drugs that mimic the action of those
mutations might also mimic their
life-prolonging effects.
For the past
few years, a group led by Longo has been
studying a few hundred Ecuadorians who
appear immune to cancer. Members of this
isolated mountain community share a mutation
that makes them insensitive to human growth
hormone - resulting in dwarfish stature but
possibly lowering the risk of cancer, since
the same genetic pathway has been linked to
tumor growth.
Longo’s group
is trying to verify whether the Ecuadorian
subjects are truly resistant to cancer and
whether they live longer than other
populations. A related group with a mutation
inherited from only one parent holds special
interest: Subjects in this group are of
normal height, yet may still possess unusual
cancer resistance. Results from the
Ecuadorian study are not expected for
several years.
At USC’s Davis
School and in laboratories around the
university, biologists focus their energy on
credible strategies for lifespan extension -
while also collaborating with demographers,
sociologists, social workers and
psychologists in a broader discussion of
aging - not as an avoidance of disease, but
as a natural condition of life.
THE BULK OF
LIFESPAN extension,
to date, has come from improved public
health: clean water, better hygiene,
immunizations, safer childbirth. Modern
medicine has lowered mortality from heart
disease somewhat and lowered cancer rates
very slightly since 1990 (cancer mortality
had risen steadily up to that point). In
1996, Finch and colleague Malcolm Pike of
the Keck School of Medicine of USC authored
an influential paper suggesting that 120
years would be a feasible average human
lifespan if caloric restriction worked as
well in people as in mice. (So far only one
human has lived past 120: Jeanne Calment of
France, who died in 1997 at age 122.)
We are moving
slowly toward a triple-digit lifespan. Life
expectancy for a person born in the United
States today is about 78 years - up from 71
years in 1970, and 60 years in 1930.
But the rising
numbers mask deterioration. The age curve is
starting to level off, or at least to rise
more slowly. Medical technology keeps some
people breathing who may not wish to keep
living - not just the brain-damaged on
ventilators, but older adults on pacemakers
and other devices whose minds decline while
their artificially supported bodies show
stubborn stamina.
Even with
technology prolonging lives of dubious
quality, the United States lags in the race
to 120. At a conference this spring hosted
by USC’s Davis School and the Office of the
Vice Provost for Research Advancement, noted
demographer Eileen Crimmins, a professor of
gerontology at the school, showed that the
United States ranks lower than many
developed countries.
“It’s hard to
find any evidence that we’re in good shape
relative to anyplace else,” says Crimmins,
who holds the AARP Chair in Gerontology at
USC and is director of a joint USC/UCLA
center on biodemography.
Some attribute
the poor U.S. showing to violent crime and
infant mortality in the inner city -
tragedies to be sure, but ones that would
suggest a much better outlook for the middle
class. However, Crimmins’ data offer no such
comfort. She compares life expectancy
starting from age 50. Infant mortality has
no influence on her numbers, and since most
victims of crime are younger, violent death
is a negligible factor.
Instead
Crimmins blames past smoking, especially by
women; a high incidence of heart disease and
diabetes; high rates of physical disability,
possibly related to obesity and sedentary
lifestyles; and variation in disease and
mortality by class, with well-educated
Americans doing somewhat better.
“People who
are poor and have low education live shorter
and less healthy lives,” she says,
regardless of their race.
Crimmins’
frequent collaborator, University Professor
and neurobiologist Finch, described a future
in which most people will lead less healthy
lives than the wealthy few, due to rising
health care costs and uneven environmental
conditions.
“There are
very powerful counter-longevity forces that
are building,” says Finch. “Future benefits
of longevity may be limited to a very small
privileged group of people.”
Against that
backdrop, how can the average person stay
healthy longer?
LEAVING FOOD
AND LOVING IT
Biologists
agree that only one strategy has been shown
to extend lifespan in a range of animals. As
often happens, it is the least pleasant
option in the spectrum of alleged anti-aging
remedies, which includes such enticing
elixirs as red wine (for resveratrol, a
much-touted but unproven tonic), blueberries
(for their anti-oxidant properties) and
growth hormones (for their libido- and
muscle-building capacity).
The strategy
is caloric restriction - a euphemism for
staying hungry. As early as the 1930s,
scientists noticed that mice fed a
low-calorie diet lived longer than their
counterparts that were fed a normal diet.
Scientists speculate that partial starvation
drives organisms into a highly
stress-resistant state, what Longo calls a
“maintenance mode.” He views caloric
restriction - or CR - as a way to fool the
body into holding out for better times. The
strategy seems to act as a natural kind of
genetic engineering, reducing the activity
of key genes involved in growth and
development but linked to cancer later in
life.
A study in
macaque monkeys is starting to yield
results. Begun in 1989 at the University of
Wisconsin by Richard Weindruch, who like
Longo is a former graduate student of
caloric-reduction pioneer Roy Walford of
UCLA, the study shows that underfed monkeys
develop far fewer age-related disorders such
as cancer, diabetes and heart disease.
Unfortunately, they also are more likely to
die from unusual causes (caloric restriction
has been linked to a weakened immune
system).
Overall the
calorie-restricted monkeys seem to live
longer, but the difference so far is not
statistically significant.
The case for
CR developed complications this year with
the release of a study by James Nelson, a
former graduate student of Finch now at the
University of Texas Health Science Center.
Nelson compared 41 genetically engineered
strains of mice and found that more strains
lived shorter lives with caloric restriction
than actually benefited. (Longo cautions
that Nelson’s mice had their caloric intake
cut almost in half, making it likely that
many simply starved.)
Four years
earlier, Nelson’s UT colleague Steven Austad
had shown that caloric restriction does not
work on wild mice, raising the possibility
that the whole thing may be a laboratory
effect.
In a paper
published last year in Proceedings of the
National Academy of Sciences, Mark Mattson
of the National Institute on Aging
questioned the value of studies based on lab
mice. He noted that lab mouse populations
are unnatural in several ways. For example,
they are bred to reproduce very quickly and
grow very fat with no limit on their food
intake.
There had
always been CR skeptics among longevity
researchers, but until recently Mattson
wasn’t one of them. “He was one of the
defenders of this idea that caloric
restriction is universal,” says Raj Sohal, a
professor in the USC School of Pharmacy.
Sohal himself
was an early believer and co-author, with
Weindruch, of an influential Science paper
on caloric restriction. Sohal has since
qualified his enthusiasm, as in a widely
publicized study with Michael Forster of the
University of North Texas that compared a
fat and a lean mouse strain and found that
caloric restriction helped only the chubby
mice.
Critics point
to these studies as proof that results from
lab mice do not apply to humans. But
consider the following laboratory
population:
• Three quarters of males and nearly
two-thirds of females are overweight or
obese.
• Specimens have access to cheap,
energy-dense food around the clock.
• Abundant calories help the young develop
and reach reproductive age faster than their
counterparts in food-scarce environments.
• Opportunities for physical activity are
limited.
THAT DESCRIBES Americans
today, according to scores of studies,
including the latest weight statistics from
the Centers for Disease Control.
“Humans are
behaving exactly like lab mice and rats,”
Sohal says, with evident disgust.
So maybe
caloric restriction could work for today’s
couch potatoes. But even a caloric
restriction enthusiast like Longo urges
caution, pending the results of two clinical
trials with some brave and very disciplined
human volunteers.
“These guys
are super skinny. I look skinny; imagine me
minus 20 pounds,” he says, pointing to his
six-foot, 172-pound frame. “The point of
these diets is to get you to weigh 25
percent less than normal.
“It’s very
extreme, too extreme,” he says. And
unproven.
Instead, Longo
supports time-tested diets such as those
followed by the long-lived people of
Okinawa: meals rich in vegetables, whole
grains and fish, complemented by physical
activity and governed by the principle of
hara hachi bu (eat only until 80 percent
full). Or, closer to Longo’s own ancestry,
the Mediterranean diet of his Southern
ltalian parents.
“Hamburgers?
Even chicken was out of the question,” Longo
said. “They ate a lot of vegetables, not
that much fruit actually, when they could
get their hands on it some cheese - a little
bit - but other than that, it was grains,
whole grains a lot of the time, and that’s
it. And meat was just once a month.
“My father is
85 and he eats meat sometimes, but most of
the time he eats a pretty good diet: green
beans, some pasta, a lot of other vegetables
thrown in there, carrots and leafy greens.
“Not
surprisingly, now they (Southern Italians)
are one of the longest lived in the world,
together with the Japanese. Is it going to
last? No, because the new Italians are
eating like Americans.”
Caloric
restriction may leave its biggest mark in
the cancer clinic. In March 2008, Longo
surprised the medical community with a study
showing that tumor-carrying mice forced to
fast before chemotherapy showed fewer side
effects and tolerated higher doses than
normally fed mice.
Longo
theorized that short-term starvation drove
healthy cells into a stress-resistance
maintenance mode, but didn’t slow the
activity of cancer cells.
That would
make all the difference in chemotherapy,
which attacks the most rapidly dividing
cells. In theory, Longo’s group had found a
way to protect healthy cells during
treatment.
Because
fasting can be dangerous, especially for
weakened individuals, Longo urges cancer
patients not to try it on their own.
Clinical trials at USC Norris Cancer
Hospital and at the Mayo Clinic in
Rochester, Minn., are testing the safety of
this approach in humans.
ELIXIR OF
YOUTH
There is an
elixir of youth, and its name is youth. All
substitutes have failed the test.
It sounded too
good to be true: You could enjoy red wine
and longer life. Soon after its discovery in
2003, a grape ingredient called resveratrol
made headlines in media from the British
tabloids to The New York Times. In 2008, the
group behind resveratrol, led by David
Sinclair of Harvard Medical School, sold its
small company to GlaxoSmithKline for $720
million - and no doubt celebrated with a
fine glass of red.
Resveratrol
and related compounds still might prove
their value in ongoing clinical trials
against adult-onset diabetes, inflammation
and cardiovascular disease. But as the
journal Nature reported this year,
scientists see technical flaws in the
experiments that made resveratrol famous.
Further, a Pfizer-funded study concluded
that resveratrol and related compounds were
dubious drug candidates due to their many
potential side effects.
Recently, two
more studies came out. One, in the journal
Cell, claimed that the gene allegedly
activated by resveratrol - SIRT1 - slows
Alzheimer’s symptoms in mice engineered to
over-express the gene.
A study in The
Journal of Neuroscience, led by Valter
Longo, found that while SIRT1 is important
for learning and memory, over-expressing the
gene does not improve cognition in mice.
“This is a
very controversial topic since [proteins in
the SIRT1 family] have been shown to be both
good and bad,” Longo notes. “In our previous
studies [in mice and mammalian cells], for
example, we showed that it was the absence
of SIRT1 that protected neurons.”
At the very
least, the conflicting results suggest that
taking a walk around the block may do more
good than driving to Walgreens for
resveratrol pills.
Widely
prescribed for lowering cholesterol, statins
also appear to reduce inflammation, which
Finch and others have linked to aging and
cell damage.
“The great
question,” says Finch, “is, ‘What can we
learn from existing anti-inflammatory drugs
and diet manipulations that influence the
inflammatory process that are going to be
applicable to maintaining human health?’ ”
Statins may
yet help scientists probe the connection
between inflammation and aging. But whether
statins themselves prolong life remains an
open question.
“Everybody
thinks statins do good things, and so nobody
wants to rock the boat,” Crimmins says. But
when she and a group of geriatrics
researchers from UCLA submitted an article
to a leading journal showing that statins
used in the treatment of cholesterol have no
effect at all on survival in old people, the
article was rejected.
“Honestly, I
was shocked,” she recalls. “The editors
said, ‘We’re not interested in this paper
because the use of statins is so ingrained
in practice right now that it would upset
things too much to say this kind of thing.’
“We don’t know
what the statins are doing,” she adds. “But
everybody thinks that statins in theory
should be good for a lot of things, not just
cholesterol; that they should lower your
inflammatory burden; maybe they are good for
your cognition.”
If a food’s
marketing literature, and maybe even the
food itself, is “loaded with powerful
anti-oxidants,” will it help you live
longer? No one would love to say yes more
than Kelvin Davies, a top authority on the
damage caused by oxidative stress. Holder of
the James E. Birren Chair in Gerontology
with a joint appointment in molecular
biology in USC College of Letters, Arts and
Sciences, Davies coined the term “oxygen
paradox” to describe the conundrum facing
almost all life on earth. Animals need
oxygen to breathe, but respiration produces
free radicals - highly reactive and toxic
oxygenated byproducts.
Davies also
discovered two “mechanics” in the cell that
break down proteins damaged by free
radicals. For reasons unknown, the mechanics
slow down with age, and eventually close up
shop.
Davies’
findings echo research on fruit flies by
John Tower, a professor of computational and
molecular biology in USC College who has a
joint appointment in the USC Davis School.
Tower’s group showed that free radicals can
serve as useful and necessary carriers of
signals between cells. During youth and
middle age, the cells’ mechanics, such as
those discovered by Davies, fix any damage
done by free radicals.
But in the
last third of life, say Davies and Tower,
something goes wrong.
“Our ability
to get rid of damaged proteins seems to be
declining - are we making abnormal proteins
at a greater rate, or are we failing to get
rid of them?” Tower asks.
Scientists are
no different than others in hoping for
clear, simple solutions. For a long time, it
seemed that aging boiled down to accumulated
damage from oxidative stress. Now, Davies
says that when he is “very honest” with
himself, he sees a cloudy picture: one that
involves some increase in oxidative stress
and some decrease in the body’s ability to
remove and repair damage - with the two
changes feeding on each other and causing an
exponentially rapid mental and physical
decline in old age.
Davies’
colleague John Walsh, associate professor of
gerontology, believes oxidative stress plays
a leading role in the part of the body that
he studies: the basal ganglia, a region of
the brain involved in motor function and
movement disorders such as Parkinson’s
disease.
Because the
brain consumes more energy than any other
organ, it contains more mitochondria - the
energy factories of the cell. Mitochondria
convert oxygen into useful energy and spit
out free radicals as byproducts. The more
mitochondria, the more free radicals.
In addition,
biologists agree that mitochondria degrade
through chance DNA mutations, leading to
greater production of free radicals with
age.
“The more of
these mitochondria you have,” Walsh says,
the more prone you are to damage. “Two
percent of the time, just because of the
randomness of biology, you’re going to be
generating free radicals in normal
mitochondria.”
If this is
true, why can’t you just load up on
anti-oxidant blueberries and be fine?
Maybe it is a
question of timing and delivery, Walsh
speculates.
Davies is
skeptical. He doubts higher doses or better
delivery would help. First, the body
contains thousands of different free
radicals, and vitamins C and E fail to take
out some of the most common types.
On a chemical
level, Davies sees a point of diminishing
returns where ingesting more anti-oxidant
molecules will bring little benefit. Whether
a river is lined with 100 or 200 fishermen
during salmon season, some fish will always
get away.
In addition,
vitamin A has been shown to raise the risk
of lung cancer and vitamin C seems to
protect cancer cells.
So load up on
powerful anti-oxidants if you wish, but
realize that beyond a common-sense dose,
they offer scarce protection and may carry
unexpected risks.
ELIXIR OF
YOUTHFULNESS?
Estrogen and
testosterone supplements may not help people
live longer. They might even kill you
sooner. But they could make the ride to
oblivion more enjoyable.
In 1994, when
Finch was directing USC’s Alzheimer Disease
Research Center (now headed by Keck School
neurologist Helena Chang Chui) and musing
aloud about a possible link between dementia
and estrogen, his then-colleague Victor
Henderson gathered surprising data from
women living in the Leisure World retirement
community in Laguna Woods, Calif.
“Among women
who had used hormone therapy, the dementia
prevalence was about 50 percent lower,”
Finch recalls. “It was a very strong
correlation. That is one of the key pieces
of evidence in the chain that has led to
this really quite large field: studying
hormones in relation to Alzheimer’s.”
Correlation
does not equal causation, but the link made
sense to many biologists. Estrogen is
critically involved in the production of
energy, and the brain is the most
energy-intensive organ in the body. It
seemed plausible that a lack of estrogen
might contribute to neural deterioration.
More than two-thirds of Alzheimer’s disease
victims are women.
In a
long-running study in Baltimore, Alzheimer’s
disease in men also has been linked to low
hormone levels. The latest data suggest that
men in the study who developed Alzheimer’s
had low testosterone even when healthy.
“Low
testosterone seems to occur prior to the
development of dementia,” says USC Davis
School gerontologist Christian Pike, whose
team studies sex hormones and the
development of Alzheimer’s disease. “In that
case it’s likely one of many contributing
factors.”
When given to
neutered rats with low libido, testosterone
makes them “all better,” Pike says.
Disgraced cyclist Floyd Landis demonstrated
testosterone’s power in an amazing solo ride
over a mountain stage of the 2006 Tour de
France. The amazement was not limited to
fans. Tour officials and medical experts
were amazed at the testosterone levels in
the two positive urine samples from Landis
that day - levels so high they could not
have been reached naturally.
So why not
prescribe testosterone for all middle-aged
men? Pike admits that more men are getting
prescriptions for the hormone and, so far,
conclusive evidence of major health risks is
lacking. Every time Pike talks about his
research at a social event, some older man
half-jokingly volunteers for a trial.
“The most
reproducible effects are decreased fat,
increased muscle,” Pike says. “You’re going
to be leaner, trimmer, feel better.”
But he does
not plan to use the hormone, and he has
advised his father not to take it either.
“It’s one of
those hot anti-aging drugs,” he says. “But
any time something like that comes along,
you have to be nervous because you don’t
know what all of its effects are.
“You wait.
There’s going to be some downsides.”
Not a day
after this was written, a study linked
testosterone supplements to an increased
risk of heart attacks.
Testosterone
therapy may wind up driving off the same
cliff as estrogen replacement. Millions of
women stopped taking estrogen in 2004 after
a massive trial showed little benefit and an
increased risk of stroke. A trial of
estrogen in combination with progestin had
been stopped earlier, in 2002, due to an
increased risk of breast cancer, coronary
heart disease, stroke and pulmonary
embolism. (The studies also found some
benefits, notably a decreased risk of bone
fractures and colorectal cancer.)
The news was a
major setback for estrogen therapy
researchers. USC’s Roberta Brinton considers
herself an exception. Professionally, she
believes her research shows that estrogen
has a “healthy cell bias,” improving brain
function when the organ is healthy but
making matters worse when neurons
degenerate.
Personally,
Brinton continues taking estrogen to counter
symptoms of menopause and, she believes, to
lower her risk of Alzheimer’s disease.
Brinton, a
professor in the USC School of Pharmacy with
joint appointments in engineering and
medicine, was featured in a New York Times
Magazine feature that explored the “timing
hypothesis”: that estrogen may be helpful
against Alzheimer’s if started early, during
or soon after menopause.
Other
scientists caution that estrogen therapy
carries a risk of serious health problems
whether started early or late. It is clear
that the loss of estrogen during menopause
imposes a tremendous burden on some women.
“We’re on the
clock,” Brinton says of her team’s battle to
vindicate estrogen therapy just as a massive
wave of Baby Boomers approaches a point
where the mind will fail before the body.
“Women can now
expect to live a third of their lifetime in
the post-menopausal state. We now know this
has profound implications for the brain and
particularly for its ability to convert
glucose into the energy the brain needs to
function. I liken it to that 30 percent drop
in people’s stock portfolio, which many have
experienced during this recession. It didn’t
kill you, but it really hurt.”
Some women
make up the loss, or at least adjust fairly
well. Others need help to recover. Others,
for poorly understood reasons that may
include estrogen depletion, begin the slide
into dementia.
In a long-term
clinical trial at the Keck School of
Medicine, faculty members Wendy Mack and
Howard Hodis are testing different
combinations of estrogen and progesterone in
the hope of finding a safe hormone
replacement therapy.
Finch, Brinton
and Pike are starting joint work on a
research grant to study the link between
hormone therapy and inflammation. Estrogen
deficits seem to impair the body’s ability
to fight inflammation, Finch says.
Taxpayers
should be rooting for Brinton. If lifespan
keeps increasing and no one figures out how
to slow Alzheimer’s, society will face a
staggering financial and emotional burden.
Health care
economist Dana Goldman, director of USC’s
new Leonard D. Schaeffer Center for Health
Policy and Economics, a collaboration
between the USC School of Pharmacy and the
School of Policy, Planning, and Development,
is an optimist on lifespan and a pessimist
on Alzheimer’s.
“Cancer became
a social epidemic in this country because we
finally lived longer to age into cancer,” he
says. “[Alzheimer’s] is the next social
epidemic. Our bodies will survive, but now
we have to figure out how to keep our minds
in shape.”
As hard as
cancer can be on a patient’s family,
Alzheimer’s represents a lower circle of
hell.
“Cognitive
decline from Alzheimer’s affects everybody
in a very fundamental way,” Goldman says.
“When you can’t recognize your family
members but they have to take care of you,
that imposes an incredible amount of wear
and tear on the other family members.
Cognitive decline is infectious in a
different way than infectious disease.”
It is hard
enough to look after normally aging
relatives. William Vega is learning this
firsthand as he tries to balance his
responsibilities as a parent, as director of
the Edward R. Roybal Institute on Aging in
the USC School of Social Work and as dutiful
son to aging in-laws who require expensive
home care.
Vega’s mission
as institute director is to help people age
in their own homes and their own
communities. It is easier said than done.
(Jon Pynoos of the USC Davis School has been
working on this issue for more than 30
years, both with home design and
fall-prevention strategies.)
Consider an
octogenarian couple. An 84-year-old woman is
going to have a real problem lifting her
husband off the floor when he falls, Vega
says.
As chair of
the prestigious Institute of Medicine’s
Health Care Disparities Roundtable, Vega has
spent years studying the social and
financial stress on families who lack access
to health care. They experience a vicious
cycle where financial stress leads to
emotional and health stress, which leads to
more financial stress, and so on.
“We already
know that low-income people age faster than
upper-income people,” he says. The
difference is already apparent by age 25:
more than a six-year gap in expected
lifespan, according to Vega.
And today’s
children are more likely to lack the
economic opportunities enjoyed by their
parents, Vega believes.
While awaiting
a breakthrough in Alzheimer’s research,
worried individuals should know that DNA is
not destiny. Decades-long studies on twins
by USC psychologist Margaret Gatz and others
have found big societal influences on
cognitive health and aging. Studies have
shown the protective value of love,
friendships and social networks, not just
against Alzheimer’s but to slow aging
overall.
In a paper
published this year in the freely accessible
PLoS Medicine journal, researchers from
Brigham Young University analyzed dozens of
studies on longevity and social ties, and
concluded that having strong networks of
friends, family and colleagues improves
one’s odds of survival by as much as 50
percent.
The
long-running Australian Longitudinal Study
of Aging found similar benefits for
participants with strong friendships.
It is a
message you will never hear from the
pharmaceutical lobby: A supplement is no
substitute for a friend.
ELIXIR OF AGE
Aside from the
stereotypical (and not entirely true)
decline in function, libido, earning power
and mental sharpness, aging is just
terrific. That is the conclusion of several
studies that consistently show an increase
in happiness as people enter their 60s. This
“positivity effect” intrigues gerontologist
Mara Mather, a young associate professor in
the USC Davis School.
Mather has
been conducting brain-imaging studies to try
to understand the phenomenon. First she
wondered if fear-related areas of the brain
simply shrank as the brain aged. But that
does not seem to be the case, Mather says.
Her initial
results suggest that older adults redirect
their brains to positive thoughts without
even realizing it.
“They tend to
be more likely than younger adults to ignore
negative information,” she says. “A larger
percentage of what they remember tends to be
positive.”
To test her
conjecture that the positivity effect stems
from willful effort, Mather tracked the time
older adults spent looking at a series of
positive and negative images. If allowed to
concentrate, the study volunteers looked
mainly at positive images. But if Mather
added a distracting sound or visual cue to
the test, older subjects were no more
positive than young adults.
“If they had a
cognitive load, they were unable to focus
more on the positive things,” Mather says.
Whether
consciously or not, USC Davis School dean
Gerald Davison finds it easy to focus on the
positive things.
Professionally, he heads a resurgent school
in a growth industry. Programs such as USC’s
Los Angeles Caregiver Resource Center and
Tingstad Older Adult Counseling Center serve
the entire region. For a school in what is
still a niche field, student enrollment is a
healthy 50 to 60 undergraduates, 100
professional master’s students and around 25
Ph.D.s, and enrollments have been increasing
over the past few years. The school just
added two junior faculty: molecular
biologist Sean Curran, a UCLA Ph.D. fresh
from a post-doctoral position at Harvard
Medical School and Massachusetts General
Hospital; and psychologist Cleopatra Abdou,
also a UCLA Ph.D. and, more recently, a
Robert Wood Johnson Foundation scholar
studying nonmaterial factors that influence
happiness.
Personally,
Davison is having the time of his life.
“Your
priorities change as you get older, and
there are things that you can no longer do
as much, but they’re not as important as
they used to be,” he says.
“Younger
people have looked at older people and said,
‘My God, you don’t taste as much, you don’t
see as well, you don’t get as much sex, your
friends are dying ... who wouldn’t be
depressed?’
“That’s the
limited perspective of the younger person.
What they’re really saying is, ‘Given my
45-year-old self, I look at those losses
with horror, I say, oh God, those poor
people.’
“And
apparently that’s not the case for most
older people, the ones who have a reasonable
amount of health. And these days there are
more and more of them.”